Información del artículo
Resumen
Presentamos un paciente con diagnóstico de Osteoporosis Juvenil Idiopática a quien se administró ácido zolendrónico, y una serie de pacientes con diagnóstico de Osteogénesis Imperfecta tratados con pamidronato durante varios años.
Se describen las imágenes osteocondensantes que aparecen en los huesos tubulares y la pelvis de estos pacientes a consecuencia de su tratamiento con bisfosfonatos, similares a las líneas de Harris (Growth Arrest Lines) que aparecen eventualmente por diversas causas en el esqueleto inmaduro.
Palabras clave:
osteoporosis juvenil idiopática
osteogénesis imperfecta
bifosfonatos
radiografía
bandas osteocondensantes
líneas de Harris
Summary
We present one patient with Juvenile Idiopathic Osteoporosis (JIO) who was treated with Zolendronic Acid, and a small series Osteogenesis Imperfecta (OI) patients administered on eyelie Pamidronate proteol.
We describe dense lines in radiographs of tubular bones and pelvis of these patients appearing. After bisphosphonates treatment, those images are similar to Harris Lines (Growth Arrest Lines) that appear occasionally by several causes on immature skeletons land through life.
Key words:
juvenile idiopathic osteoporosis
osteogenesis imperfecta
bisphosphonates
radiographs
radiodense lines
Harris lines
El Texto completo está disponible en PDF
Referencias
[1.]
M.L. Bianchi.
Osteoporosis in children and adolescents.
Bone, 41 (2007), pp. 486-495
[4.]
R.S. Lorenc.
Idiopathic juvenil osteoporosis.
Calcif Tissue Int, 70 (2002), pp. 395-397
[5.]
F. Rauch, R. Travers, M.E. Norman, et al.
The bone formation defect in idiopathic juvenile osteoporosis is surface-specific.
Bone, 31 (2002), pp. 85-89
[6.]
S.A. Bowden, R.F. Robinson, R. Carr, J.D. Mahan.
Prevalence of vitamin D deficiency and insufficiency in children with osteopenia or osteoporosis referred to a pediatric metabolic bone clinic.
Pediatrics, 121 (2008), pp. e1585-e1590
[7.]
D. Chlebna-Sokol, A. Rusinska.
Serum insuline/like growth factor I, bone mineral density and biochemical markers of bone metabolism in children with idiopathic osteoporosis.
Endocr Regul, 35 (2001), pp. 201-208
[8.]
H. Hartikka, O. Mäkitie, M. Männikkö, et al.
Heterozygous mutations in the LDL receptor related protein 5 (LRP5) gene are associated with primary osteoporosis in children.
J Bone Miner Res, 20 (2005), pp. 783-789
[9.]
M.S. Cheung, F.H. Glorieux.
Osteogenesis imperfecta: Update on presentation.
Rev Endocr Metab Dis, 9 (2008), pp. 153-160
[10.]
F. Rauch, F.H. Glorieux.
Osteogenesis imperfecta.
Lancet, 363 (2004), pp. 1377-1384
[11.]
M.T. Drake, B.L. Clarke, S. Khosla.
Biphosphonates: Mechanism of action and role in clinical practice.
Mayo Clin Proc, 83 (2008), pp. 1032-1045
[12.]
L.I. Plotkin, V. Lezcano, J. Thostenson, et al.
Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo.
J Bone Miner Res, 23 (2008), pp. 1712-1721
[13.]
N.J. Shaw, C.M. Boivin, N.J. Crabtree.
Intravenous pamidronate in juvenile osteoporosis.
Arch Dis Child, 83 (2000), pp. 143-145
[14.]
E. Unal, A. Abaci, E. Bober, A. Büyükgebiz.
Efficacy and safety of oral alendronate treatment in children and adolescents with osteoporosis.
J Pediatr Endocrinol Metab, 19 (2006), pp. 523-528
[15.]
R. Melchior, B. Zabel, J. Spranger, R. Shumacher.
Effective parenteral clodronate treatment of a child with severe juvenile.
Eur J Pediatr, 164 (2005), pp. 22-27
[16.]
S.L. Silverman, R. Landesberg.
Osteonecrosis of the jaw and the role of bisphosphonates: a critical review.
JAMA, 122 (2009), pp. S33-S45
[17.]
J.C. Marini.
Do bisphosphonates make children's bones better or brittle?.
N Engl J Med, 349 (2003), pp. 423-426
[18.]
C.A. Phillipi, T. Remmington, R.D. Steiner.
Bisphosphonate therapy for osteogenesis imperfecta.
Cochrane Database of Systematic Reviews, 4 (2008),
[19.]
L. Ward, A. Tricco, P.N. Phuong, et al.
Bisphosphonate therapy for children and adolescents with secondary osteoporosis.
Cochrane Database of Systematic Reviews, 4 (2007),
[20.]
Lazala O. Osteogénesis imperfecta. 2001. Monografía presentada al Consejo Directivo de la Facultad de Medicina, para optar a la categoría de Profesor Asociado.
[21.]
L.E. Grissom, H.T. Harcke.
Radiographic features of bisphosphonate therapy in pediatric patients.
Pediatr Radiol, 33 (2003), pp. 226-229
[22.]
G. Quintana, A. Fernández, J.F. Restrepo, et al.
Osteomesopicnosis asociada a litiasis renal. Informe de un caso. Diagnóstico diferencial de las enfermedades osteoesclerosantes axiales.
Revista Colombiana de Reumatología, 11 (2004), pp. 341-348
[23.]
C. Onwuneme, K. Abdalla, N. Cassidy, et al.
Radiological findings in cyclical administration of intravenous pamidronate in children with osteoporosis.
Arch Dis Child, 92 (2007), pp. 1087
[24.]
S. Ameen, L. Staub, S. Ulrich, et al.
Harris lines of the tibia across centuries: a comparison of two populations, medieval and contemporary in Central Europe.
Skeletal Radiol, 34 (2005), pp. 279-284
[25.]
O. Nowak, J. Piontek.
The frequency of appearance of transverse (Harris) lines in the tibia in relationship to age at death.
Ann Human Biol, 29 (2002), pp. 314-325
[26.]
M. Al Muderis, T. Azzopardi, P. Cundy.
Zebra lines of pamidronate therapy in children.
J Bone Joint Surg Am, 89 (2007), pp. 1511-1516
[27.]
E.N. Vinson, Clinical Image:.
Pamidronate “zebra” lines.
Arthritis Rheum, 58 (2008), pp. 2817
Copyright © 2009. Asociación Colombiana de Reumatología
